Clinical trials: Non-Small Cell Lung
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non-small Cell Lung Cancer
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant…
- Trial name
- neovision (NCT06734182)
- Testing
- Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Guangdong Provincial People's Hospital
Non Small Cell Lung Cancer, BRAF V600E
ENCOrafenib With Binimetinib in bRAF NSCLC
A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
- Trial name
- ENCO-BRAF (NCT04526782)
- Testing
- Encorafenib 75 MG, Binimetinib 15 MG
- Where
- 36 sites in France
- Volunteers
- 119 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non-small Cell Lung Cancer
Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens
The purpose of the study is to determine if rapid on-site evaluation of EBUS-TBNA samples can increase the percentage of patients with advanced non-squamous non-small cell lung cancer in whom both pathologic subtyping and…
- Trial name
- NCT01799382
- Testing
- Rapid on-site evaluation, EBUS-TBNA
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Maggiore Bellaria Hospital, Bologna
Squamous Non-small Cell Lung Cancer
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
The purpose of the Phase 1b portion of the study is to investigate how the body tolerates necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line treatment in participants with Stage IV squamous…
- Trial name
- NCT01763788
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 20 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer…
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03050060
- Testing
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Lung Cancer
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Giving autologous lymphocytes that have been treated in the laboratory with antibodies may stimulate the immune system to kill tumor cells. Aldesleukin may stimulate the lymphocytes to kill tumor cells.
- Trial name
- NCT00569296
- Testing
- EGFRBi-armed autologous activated T cells, aldesleukin, sargramostim
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roger Williams Medical Center
Carcinoma, Non-Small-Cell Lung
Temsirolimus and Radiation for Non-Small Cell Lung Cancer
To determine the maximum tolerated dose of the drug temsirolimus given with radiation therapy for patients with non-small cell lung cancer.
- Trial name
- NCT00796796
- Testing
- Temsirolimus, Radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per…
- Trial name
- DUART (NCT04249362)
- Testing
- Durvalumab
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Gilteritinib for the Treatment of ALK NSCLC
This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments.
- Trial name
- NCT06225427
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-Small Cell Lung Cancer
Gut Microbiota and Cancer Immunotherapy Response
This study will analyze the composition and diversity of the gut microbiota of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) through metagenomic high-throughput sequencing methods, and explore…
- Trial name
- NCT04682327
- Testing
- Response to anti-PD-1/PD-L1, Non-response to anti-PD-1/PD-L1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Lung Cancer
Organoid-guided Personalized Treatment of Pleural Effusion
The study is a single-arm, single-center clinical research that utilizes patient-derived tumor organoids to predict drug sensitivity, thereby assisting clinicians in formulating treatment plans to benefit lung cancer patients…
- Trial name
- NCT06959173
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer
Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer
NSCLC is the leading cause of cancer mortality in North America, accounting for nearly 30% of all cancer deaths. The standard treatment for patients with early-stage non-small-cell lung cancer (NSCLC) is surgical resection of the…
- Trial name
- NCT01480973
- Testing
- Stereotactic Body Radiation Therapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
NSCLC, Renal Cell Carcinoma
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also…
- Conditions
- NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma
- Trial name
- HYPOGRYPHE (NCT05703269)
- Testing
- single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
- Where
- 34 sites in United States
- Volunteers
- 58 people
- Sponsor
- Wake Forest University Health Sciences
Carcinoma, Non-Small-Cell Lung
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Using a laboratory test (VeriStrat), patients with relapsed squamous cell lung cancer are assigned to two strata, VSG (VeriStrat Good) and VSP (VeriStrat Poor).
- Trial name
- EMPHASIS (NCT01652469)
- Testing
- Erlotinib, Docetaxel
- Where
- 32 sites in Austria, Belgium and 10 more
- Volunteers
- 81 people
- Sponsor
- ETOP IBCSG Partners Foundation
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung carcinoma (NSCLC) - stage IIIB/IV.
- Trial name
- iTRAP (NCT03498222)
- Testing
- Atezolizumab, Pemetrexed, Carboplatin
- Sponsor
- Queen Mary University of London
Lung Cancer
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003202
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumors
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer.
- Trial name
- NCT04999202
- Testing
- BAY2416964, Pembrolizumab
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 47 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.